Biomarkers in Primary Prevention : Meaningful Diagnosis Based on Biomarker Scores?

Overview

Journal Herz

Specialty Cardiology & Vascular Diseases

Date 2019 Dec 7

PMID 31807790

Citations 5

Authors

Christian Schulte

Tanja Zeller

Affiliations

Soon will be listed here.

Abstract

Cardiovascular (CV) risk assessment is based on the utilization of risk scores, enabling clinicians to estimate an individual's risk to develop CV pathologies and events. Such risk scores comprise classic CV risk factors such as smoking, diabetes, hypertension, and blood cholesterol levels. Recently, other CV biomarkers such as cardiac troponins have been suggested and evaluated as alternative biomarkers not only in the acute diagnostic setting of myocardial infarction, but also as markers for risk stratification in the general population. In this review, we summarize the current knowledge on biomarkers in the field of primary prevention in cardiovascular disease (CVD). Furthermore, we present potential alternative biomarker-based strategies for CV risk assessment. In this respect we provide an outlook on the potential use of genomic variation as well as circulating non-coding RNAs to complement current risk assessment strategies so as to further personalize risk stratification in CVD.

Citing Articles

DNA and RNA Molecules as a Foundation of Therapy Strategies for Treatment of Cardiovascular Diseases.

Rakicevic L Pharmaceutics. 2023; 15(8).

PMID: 37631355 PMC: 10459020. DOI: 10.3390/pharmaceutics15082141.

Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review.

Sethi Y, Patel N, Kaka N, Kaiwan O, Kar J, Moinuddin A J Clin Med. 2023; 12(5).

PMID: 36902588 PMC: 10003116. DOI: 10.3390/jcm12051799.

High sensitivity troponins: A potential biomarkers of cardiovascular risk for primary prevention.

Leite L, Matos P, Leon-Justel A, Espirito-Santo C, Rodriguez-Padial L, Rodrigues F Front Cardiovasc Med. 2022; 9:1054959.

PMID: 36531726 PMC: 9748104. DOI: 10.3389/fcvm.2022.1054959.

Biomarkers for Heart Failure Prognosis: Proteins, Genetic Scores and Non-coding RNAs.

Shrivastava A, Haase T, Zeller T, Schulte C Front Cardiovasc Med. 2020; 7:601364.

PMID: 33330662 PMC: 7719677. DOI: 10.3389/fcvm.2020.601364.

Cardiac Troponin T Release after Football 7 in Healthy Children and Adults.

Cirer-Sastre R, Legaz-Arrese A, Corbi F, Lopez-Laval I, Puente-Lanzarote J, Hernandez-Gonzalez V Int J Environ Res Public Health. 2020; 17(3).

PMID: 32033112 PMC: 7037606. DOI: 10.3390/ijerph17030956.

References

DAgostino Sr R, Vasan R, Pencina M, Wolf P, Cobain M, Massaro J . General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008; 117(6):743-53. DOI: 10.1161/CIRCULATIONAHA.107.699579. View

Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423-33. PMC: 3074610. DOI: 10.1038/ncb2210. View

Neumann J, Twerenbold R, Ojeda F, Sorensen N, Chapman A, Shah A . Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. N Engl J Med. 2019; 380(26):2529-2540. DOI: 10.1056/NEJMoa1803377. View

Anand A, Chin C, Shah A, Kwiecinski J, Vesey A, Cowell J . Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis. Heart. 2017; 104(13):1101-1108. PMC: 6031261. DOI: 10.1136/heartjnl-2017-312257. View

Williamson L, Saponaro M, Boeing S, East P, Mitter R, Kantidakis T . UV Irradiation Induces a Non-coding RNA that Functionally Opposes the Protein Encoded by the Same Gene. Cell. 2017; 168(5):843-855.e13. PMC: 5332558. DOI: 10.1016/j.cell.2017.01.019. View

Jacquet S, Yin X, Sicard P, Clark J, Kanaganayagam G, Mayr M . Identification of cardiac myosin-binding protein C as a candidate biomarker of myocardial infarction by proteomics analysis. Mol Cell Proteomics. 2009; 8(12):2687-99. PMC: 2816024. DOI: 10.1074/mcp.M900176-MCP200. View

Khera A, Chaffin M, Aragam K, Haas M, Roselli C, Choi S . Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018; 50(9):1219-1224. PMC: 6128408. DOI: 10.1038/s41588-018-0183-z. View

Schulte C, Westermann D, Blankenberg S, Zeller T . Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction. World J Cardiol. 2016; 7(12):843-60. PMC: 4691811. DOI: 10.4330/wjc.v7.i12.843. View

Marjot J, Kaier T, Martin E, Reji S, Copeland O, Iqbal M . Quantifying the Release of Biomarkers of Myocardial Necrosis from Cardiac Myocytes and Intact Myocardium. Clin Chem. 2017; 63(5):990-996. PMC: 6114147. DOI: 10.1373/clinchem.2016.264648. View

10.

McNeil J, Wolfe R, Woods R, Tonkin A, Donnan G, Nelson M . Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018; 379(16):1509-1518. PMC: 6289056. DOI: 10.1056/NEJMoa1805819. View

11.

Ganna A, Magnusson P, Pedersen N, de Faire U, Reilly M, Arnlov J . Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol. 2013; 33(9):2267-72. DOI: 10.1161/ATVBAHA.113.301218. View

12.

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

13.

Erdmann J, Kessler T, Venegas L, Schunkert H . A decade of genome-wide association studies for coronary artery disease: the challenges ahead. Cardiovasc Res. 2018; 114(9):1241-1257. DOI: 10.1093/cvr/cvy084. View

14.

Baker J, Tyther R, Liebetrau C, Clark J, Howarth R, Patterson T . Cardiac myosin-binding protein C: a potential early biomarker of myocardial injury. Basic Res Cardiol. 2015; 110(3):23. PMC: 4383815. DOI: 10.1007/s00395-015-0478-5. View

15.

Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Eur Heart J. 2016; 37(29):2315-2381. PMC: 4986030. DOI: 10.1093/eurheartj/ehw106. View

16.

Rao A, Knowles J . Polygenic risk scores in coronary artery disease. Curr Opin Cardiol. 2019; 34(4):435-440. DOI: 10.1097/HCO.0000000000000629. View

17.

Aengevaeren V, Hopman M, Thompson P, Bakker E, George K, Thijssen D . Exercise-Induced Cardiac Troponin I Increase and Incident Mortality and Cardiovascular Events. Circulation. 2019; 140(10):804-814. DOI: 10.1161/CIRCULATIONAHA.119.041627. View

18.

Arroyo J, Chevillet J, Kroh E, Ruf I, Pritchard C, Gibson D . Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108(12):5003-8. PMC: 3064324. DOI: 10.1073/pnas.1019055108. View

19.

Sigurdardottir F, Lyngbakken M, Holmen O, Dalen H, Hveem K, Rosjo H . Relative Prognostic Value of Cardiac Troponin I and C-Reactive Protein in the General Population (from the Nord-Trøndelag Health [HUNT] Study). Am J Cardiol. 2018; 121(8):949-955. DOI: 10.1016/j.amjcard.2018.01.004. View

20.

Blankenberg S, Zeller T, Saarela O, Havulinna A, Kee F, Tunstall-Pedoe H . Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010; 121(22):2388-97. DOI: 10.1161/CIRCULATIONAHA.109.901413. View